psych 1

INTIAL QUESTION; The prevailing hypothesis for schizophrenia implicates the neurotransmitter dopamine as playing a key role in the development of the disease. Dopamine acts on several areas of the brain with differing effects.

· Please outline the key dopamine pathways and the implications of antipsychotic use on each pathway (i.e., and increase vs. decrease

RESPONSE: The dopamine theory of schizophrenia proposes that abnormal dopamine activity in specific areas of the brain contributes significantly to the symptoms seen in the disorder. (Stahl, 2021). Dopamine is an important neurotransmitter involved in mood, reward, movement, motivation, and cognition (Story, 2024). In schizophrenia, some dopamine pathways are overactive while others are underactive, which helps explain the different symptoms patients experience. Antipsychotic medications mainly work by blocking dopamine D2 receptors, but these effects can impact each dopamine pathway differently (Stahl, 2021).

The mesolimbic pathway is primarily connected to the positive symptoms of schizophrenia, including hallucinations, delusions, and disorganized thoughts or behaviors. (Stahl, 2021). In this pathway, dopamine activity is increased (Story, 2024). Antipsychotic medications help decrease dopamine activity here, which is why they are effective in reducing psychotic symptoms (Gabbard, 2014). This is considered the main therapeutic target for antipsychotics.

The mesocortical pathway plays an important role in regulating mood, thinking, motivation, and emotional responses. In contrast to the mesolimbic pathway, dopamine function within the mesocortical pathway is typically reduced in individuals with schizophrenia. (Stahl, 2021). This contributes to negative symptoms such as flat affect, lack of motivation, social withdrawal, and cognitive difficulties (Correll & Schooler, 2020). Because antipsychotics also block dopamine, they can sometimes worsen these symptoms, especially first-generation antipsychotics (Correll & Schooler, 2020). Some second-generation antipsychotics may help improve dopamine balance in this pathway due to serotonin effects (Correll & Schooler, 2020).

The nigrostriatal pathway is responsible for movement and coordination (Story, 2024). Dopamine blockade within this pathway may lead to extrapyramidal side effects (EPS), such as tremors, muscle stiffness, akathisia, and tardive dyskinesia. (Stahl, 2021). This is one reason why first-generation antipsychotics tend to have more movement-related side effects (Stahl, 2021).

The tuberoinfundibular pathway controls prolactin release (Story, 2024). Dopamine normally suppresses prolactin, so when dopamine is blocked, prolactin levels rise. This can lead to side effects such as gynecomastia, galactorrhea, menstrual irregularities, and sexual dysfunction (Gabbard, 2014).

Understanding these dopamine pathways helps explain both the benefits and side effects of antipsychotic medications. As future PMHNPs, knowing how these pathways function will help us better educate patients, monitor side effects, and choose the most appropriate treatment options.

References

Correll, C., & Schooler, N. (2020). Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric Disease and Treatment, 16(1), 519–534. https://doi.org/10.2147/ndt.s225643

Gabbard, G. O. (2014). Gabbard’s treatments of psychiatric disorders (5th ed.). American Psychiatric Publishing.

Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. (5th ed.). Cambridge University Press.

Story, L. (2024). Pathophysiology: A practical approach. Jones & Bartlett Learning.